Who are Prednisolone plus Cyclophosphamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): prednisone and cyclophosphamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prednisolone-plus-cyclophosphamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prednisolone plus Cyclophosphamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prednisolone plus Cyclophosphamide (Prednisolone plus Cyclophosphamide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Alkylating agent combination. Area: Immunology / Rheumatology.

phase 3 Corticosteroid + Alkylating agent combination Glucocorticoid receptor (prednisolone); DNA (cyclophosphamide) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Prednisolone plus Cyclophosphamide (Prednisolone plus Cyclophosphamide) — Air Force Military Medical University, China. Prednisolone suppresses immune responses through glucocorticoid receptor activation, while cyclophosphamide induces immunosuppression and cytotoxicity through DNA alkylation and cross-linking.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prednisolone plus Cyclophosphamide TARGET	Prednisolone plus Cyclophosphamide	Air Force Military Medical University, China	phase 3	Corticosteroid + Alkylating agent combination	Glucocorticoid receptor (prednisolone); DNA (cyclophosphamide)
prednisone and cyclophosphamide	prednisone and cyclophosphamide	Guangdong Provincial People's Hospital	marketed	Corticosteroid + Alkylating agent combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + Alkylating agent combination class)

Air Force Military Medical University, China · 1 drug in this class
Guangdong Provincial People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prednisolone plus Cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/prednisolone-plus-cyclophosphamide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing